BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Reference Citation Analysis]
2 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
3 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Zhou TC, Liu FW, Fan JH, Zhang SH, Lv SQ, Yu ZY, Zhang YM, Zhang L, Wei J. The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years. Infect Genet Evol 2021;89:104706. [PMID: 33418145 DOI: 10.1016/j.meegid.2021.104706] [Reference Citation Analysis]
5 van den Berg F, Limani SW, Mnyandu N, Maepa MB, Ely A, Arbuthnot P. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses 2020;12:E851. [PMID: 32759756 DOI: 10.3390/v12080851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
6 Quiroga AD, Vera MC, Ferretti AC, Lucci A, Comanzo CG, Lambertucci F, Ceballos MP, Carrillo MC. IFN-α-2b induces apoptosis by decreasing cellular cholesterol levels in rat preneoplastic hepatocytes. Cytokine 2020;133:155172. [PMID: 32590329 DOI: 10.1016/j.cyto.2020.155172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, Chen B, Chen P, Mao F, Yu Q. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35:1467-1476. [PMID: 32180249 DOI: 10.1111/jgh.15036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Tang F, Huang G, Lin L, Yin H, Shao L, Xu R, Cui X. Anti-HBV Activities of Polysaccharides from Thais clavigera (Küster) by In Vitro and In Vivo Study. Mar Drugs 2021;19:195. [PMID: 33808126 DOI: 10.3390/md19040195] [Reference Citation Analysis]
9 Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
11 Korkmaz A, Top Karti D, Unsal Bilgin YO, Karti O, Celebisoy N. Bilateral Optic Neuropathy Revealing Chronic Hepatitis B Infection: A Report of A Rare Case. Neuroophthalmology 2021;45:403-6. [PMID: 34720272 DOI: 10.1080/01658107.2020.1806888] [Reference Citation Analysis]
12 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
13 Li X, Liu H, Cheng W, Wang J, Zhang H, Lu F, Chen X, Lin W. Junceellolide B, a novel inhibitor of Hepatitis B virus. Bioorg Med Chem 2020;28:115603. [PMID: 32690259 DOI: 10.1016/j.bmc.2020.115603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Omotola EO, Genthe B, Ndlela L, Olatunji OS. Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems. Int J Environ Res Public Health 2021;18:8358. [PMID: 34444108 DOI: 10.3390/ijerph18168358] [Reference Citation Analysis]
15 Koç DÖ, Özhan Y, Acar ET, Bireroğlu N, Aslan F, Keğin M, Sipahi H. Serum Neopterin Levels and IDO Activity as Possible Markers for Presence and Progression of Hepatitis B. Pteridines 2020;31:91-9. [DOI: 10.1515/pteridines-2020-0010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
17 Drake GJ, Haycock J, Dastjerdi A, Davies H, Lopez FJ. Use of immunostimulants in the successful treatment of a clinical EEHV1A infection in an Asian elephant ( Elephas maximus ). Vet rec case rep 2020;8. [DOI: 10.1136/vetreccr-2020-001158] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X. Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy. Innate Immun 2020;26:601-8. [PMID: 32772775 DOI: 10.1177/1753425920942580] [Reference Citation Analysis]
20 Thangamani L, Balasubramanian B, Easwaran M, Natarajan J, Pushparaj K, Meyyazhagan A, Piramanayagam S. GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics. Pharmacol Res 2021;173:105864. [PMID: 34474100 DOI: 10.1016/j.phrs.2021.105864] [Reference Citation Analysis]
21 Nečasová I, Stojaspal M, Motyčáková E, Brom T, Janovič T, Hofr C. Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy. NAR Cancer 2022;4:zcac005. [PMID: 35252867 DOI: 10.1093/narcan/zcac005] [Reference Citation Analysis]